Business
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical and preclinical programs advancing with defined milestonesAchieved fifth program milestone with Sanofi, totaling $134 million in payments to date; five Recursion discovery program packages have been accepted to date, establishing a growing joint portfolio of novel AI-driven small molecules for imm
About this update from Sanofi Sa
[{"type":"image","alt":"Recursion Pharmaceuticals","displaySize":"","headline":null,"caption":"Recursion Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/f578b01a9459c9f3aa40cac45d5a11b2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JEN5Rmz_tfinmvJwfVkSww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f578b01a9459c9f3aa40cac45d5a11b2","width":300,"height":64},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/JEN5Rmz_tfinmvJwfVkSww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f578b01a9459c9f3aa40cac45d5a11b2","width":300,"height":64}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical and preclinical programs advancing with defined milestones","length":260,"tagName":"p"}]},{"val":[{"type":"text","content":"Achieved fifth program milestone with Sanofi, totaling $134 million in payments to date; five Recursion discovery program packages have been accepted to date, establishing a growing joint portfolio of novel AI-driven small molecules for immunology and oncology","length":260,"tagName":"p"}]},{"val":[{"type":"text","content":"$754 million of cash and cash equivalents; exceeded original cost savings guidance and now expect runway into early 2028 without additional financing, reflecting disciplined capital allocation alongside continued platform and program investment","length":244,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":764,"olType":false},{"type":"text","content":"SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and full year ending December 31, 2025.","length":277,"tagName":"p"},{"type":"text","content":"Recursion will host an Earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT from Recursion’s X, LinkedIn, and YouTube accounts giving analysts, investors, and the public the opportunity to as...